Stocks IPHA

Innate Pharma S.A. Presents Initial Phase 1 Clinical Data for IPH4502

Innate Pharma S.A. announced initial Phase 1 clinical data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate incorporating an exatecan payload, in patients with advanced solid tumors. The Phase 1 dose-escalation study enrolled 76 patients across six dose levels ranging from 0.6 mg/kg to 3.6 mg/kg, administered once every three weeks. The primary objective of the study was to assess the safety and tolerability of IPH4502, while secondary objectives include evaluating its pharmacokinetics and antitumor activity.

As of the August 17, 2026 data cutoff, the maximum tolerated dose was established at 3.6 mg/kg administered once every three weeks, with stomatitis as the only reported dose-limiting toxicity. Grade 3 or higher treatment-emergent adverse events were reported in 43.4% of patients, including Grade 3 or higher anemia in 11.8%. At the maximum tolerated dose of 3.6 mg/kg, an objective response rate of 33% (2/6) was observed in patients with non-urothelial tumors. In urothelial cancer, 19 patients who had previously received enfortumab vedotin were enrolled, showing antitumor activity at intermediate dose levels.

Innate Pharma S.A. is initiating Phase 1 dose optimization in second-line or later urothelial cancer following enfortumab vedotin to further characterize safety and activity at upper dose levels. The first patient is planned in the first half of 2027. The study will evaluate split dosing on Days 1 and 8 of each three-week cycle with mandatory prophylaxis to help reduce stomatitis and inform selection of a recommended Phase 2 dose and schedule.

View the company filing on SEC.gov

Take Fintel with you. Download the Fintel app from the App Store or Google Play.

This story originally appeared on Fintel.

Fintel
Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford.
Check out our Unique Analysis of Insider Sentiment for Innate Pharma S.A. - Depositary Receipt (Common Stock) Find out what the Options Markets think of Innate Pharma S.A. - Depositary Receipt (Common Stock) See our take on Innate Pharma S.A. - Depositary Receipt (Common Stock) Upcoming Earnings More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available